Tozoracimab shows COPD exacerbation cuts across subgroups

Tozoracimab demonstrated reduced COPD exacerbations across patient subgroups, including those with low eosinophil counts. The therapy received FDA priority review and a potential launch in Q1 2027, with expected peak sales exceeding $5 billion.